Patent intelligence · US
US 7332224
Cleaning article containing hydrophilic polymers
Cleaning article containing hydrophilic polymers
Patent details — US 7332224
- Jurisdiction
- US
- Status
- granted
- Grant date
- Feb 19, 2008
- Expiration
- Feb 14, 2028
- Applicant
- ReGenesis Group
- Claims
- 8
- CPC classes
- A61K, A61K8/0208, A61K8/8176, A61K8/8182
Quick answer
US 7332224 (Cleaning article containing hydrophilic polymers) is held by ReGenesis Group. Status: granted. Granted Feb 19, 2008. Expires Feb 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- ReGenesis Group
- Grant date
- Expiration
- Claims
- 8
- CPC classes
- A61K, A61K8/0208, A61K8/8176, A61K8/8182, A61K8/87
More from ReGenesis Group
Related pharmaceutical patents in our USPTO index.
-
US 12428463
Chimeric antigen receptors targeting abnormal glycobiology
granted -
US 12427148
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 12428416
ERK inhibitors and uses thereof
granted -
US 12427151
Compositions and method of treating cancer
granted -
US 12427197
Methods of producing cobalt nanoparticles and hollow metal nanospheres
granted -
US 12428489
Human PD-L2 antibodies and methods of use therefor
granted -
US 12427155
Treatment for tau-related diseases
granted -
US 12428455
Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells
granted
Frequently asked questions
What is US patent 7332224?
US 7332224 (Cleaning article containing hydrophilic polymers) is held by ReGenesis Group. Status: granted. Granted Feb 19, 2008. Expires Feb 14, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 7332224?
ReGenesis Group is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 8,292 pharmaceutical patents for this assignee.
When does US 7332224 expire?
Our index shows an expiration date of Feb 14, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.